am 251 and ketamine
am 251 has been researched along with ketamine in 3 studies
Research
Studies (3)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| McMahon, LR | 2 |
| Duarte, IDG; Pacheco, DDF; Romero, TRL | 1 |
Other Studies
3 other study(ies) available for am 251 and ketamine
| Article | Year |
|---|---|
Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
Topics: Analgesics, Opioid; Anesthetics, Dissociative; Anesthetics, Intravenous; Anesthetics, Local; Animals; Benzoxazines; Camphanes; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Cannabinoids; Cocaine; Cyclohexanols; Discrimination Learning; Dose-Response Relationship, Drug; Dronabinol; Female; Hallucinogens; Ketamine; Macaca mulatta; Male; Midazolam; Morphine; Morpholines; Naphthalenes; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2 | 2006 |
Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.
Topics: Animals; Benzoxazines; Cannabinoids; Conditioning, Operant; Cyclohexanols; Discrimination Learning; Dose-Response Relationship, Drug; Dronabinol; Drug Interactions; Female; Hallucinogens; Humans; Injections, Intravenous; Injections, Subcutaneous; Ketamine; Macaca mulatta; Male; Midazolam; Morpholines; Naphthalenes; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Time Factors | 2006 |
Ketamine induces central antinociception mediated by endogenous cannabinoids and activation of CB
Topics: Analgesics; Animals; Arachidonic Acids; Cannabinoids; Dose-Response Relationship, Drug; Drug Synergism; Indoles; Infusions, Intraventricular; Ketamine; Male; Mice; Organophosphonates; Pain Measurement; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2 | 2019 |